



Vivo Biosciences Inc.

Accelerating Preclinical Research, Drug Discovery & Therapeutics

NEWS RELEASE

Vivo Biosciences Presents at US National Cancer Institute.

Birmingham, AL – August 24, 2009 – Dr. Raj Singh, President and Chief Executive Officer of Vivo Biosciences, presented an overview of the 3D HuBiogel™ Assay Platform to the National Institutes of Health's Advanced Technology Center in Gaithersburg, Maryland on August 18, 2009. The invited presentation was organized by Dr. Frank Cuttitta, Director of the NCI Angiogenesis Core Facility, NIH. Dr. Singh stated, "We appreciate the invitation and opportunity to present our promising 3D *in vitro* preclinical bioassay platform to the scientific community at the National Cancer Institute. The presentation forum provided an open exchange of scientific ideas and challenges facing *in vitro* drug discovery research today and how 3D cell modeling can address some of these questions."

About Vivo Biosciences, Inc.

Vivo Biosciences, Inc. is an emerging, venture-backed biotechnology company, incorporated in 2004 for the purpose of introducing a novel, human biomatrix, HuBiogel™, to the biological research markets. VBI strives to maximize the functional relevance & predictability of your cell-based assays. We are confident that our unique HuBiogel™ assays will improve drug efficacy/ toxicity endpoints and critical preclinical decisions.

About the HuBiogel™ Assay Platform

The 3D HuBiogel™ Assay Platform is a novel *in vitro* assay platform that recapitulates human cells in a fully human extracellular matrix. These three dimensional systems provide the drug development industry with a cost efficient assay to identify drug efficacy and toxicity. Current systems use animal based or synthetic extracellular matrices which may impact their *in vivo* predictability.

Vivo Biosciences' Contact: Lee T. Martin, Ph.D.

Source: Vivo Biosciences, Inc.

Vivo Biosciences Website: www.vivobiotech.com